OMX Copenhagen PI
1.284,56
PKT
-12,38
PKT
-0,95
%
Werbung
Analysen zu OMX Copenhagen PI-Werten
Datum | Rating | Analyst | |
---|---|---|---|
19.09.25 | Novo Nordisk Buy | Deutsche Bank AG | |
18.09.25 | Novo Nordisk Buy | Deutsche Bank AG | |
18.09.25 | Novo Nordisk Neutral | UBS AG | |
18.09.25 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
17.09.25 | Novo Nordisk Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
16.09.25 | Novo Nordisk Neutral | UBS AG | |
15.09.25 | Novo Nordisk Neutral | UBS AG | |
11.09.25 | Novo Nordisk Buy | Deutsche Bank AG | |
10.09.25 | Novo Nordisk Outperform | Bernstein Research | |
10.09.25 | Novo Nordisk Neutral | UBS AG | |
10.09.25 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
08.09.25 | Novo Nordisk Neutral | UBS AG | |
05.09.25 | Novo Nordisk Neutral | UBS AG | |
04.09.25 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
01.09.25 | Novo Nordisk Neutral | UBS AG | |
29.08.25 | Novo Nordisk Neutral | UBS AG | |
27.08.25 | Novo Nordisk Buy | Deutsche Bank AG | |
27.08.25 | Novo Nordisk Market-Perform | Bernstein Research | |
26.08.25 | A.P. Moeller - Maersk A-S (B) Underweight | JP Morgan Chase & Co. | |
21.08.25 | Novo Nordisk Buy | Deutsche Bank AG | |
19.08.25 | Novo Nordisk Neutral | UBS AG | |
18.08.25 | Novo Nordisk Neutral | UBS AG | |
12.08.25 | Novo Nordisk Neutral | UBS AG | |
11.08.25 | Novo Nordisk Market-Perform | Bernstein Research | |
08.08.25 | Novo Nordisk Neutral | UBS AG | |
08.08.25 | Novo Nordisk Buy | Goldman Sachs Group Inc. | |
08.08.25 | Novo Nordisk Halten | DZ BANK | |
07.08.25 | Novo Nordisk Market-Perform | Bernstein Research | |
07.08.25 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
07.08.25 | Novo Nordisk Buy | Deutsche Bank AG | |
06.08.25 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
06.08.25 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
06.08.25 | Novo Nordisk Neutral | UBS AG | |
05.08.25 | Novo Nordisk Neutral | UBS AG | |
04.08.25 | Novo Nordisk Buy | Goldman Sachs Group Inc. | |
01.08.25 | Novo Nordisk Market-Perform | Bernstein Research | |
30.07.25 | Novo Nordisk Equal Weight | Barclays Capital | |
30.07.25 | A.P. Moeller - Maersk A-S (B) Underweight | JP Morgan Chase & Co. | |
30.07.25 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
30.07.25 | Novo Nordisk Market-Perform | Bernstein Research |